- Home
- AUPH vs MNKD Comparison
AUPH vs MNKD Comparison
Compare AUPH & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | MNKD |
|---|---|---|
| Founded | 1993 | 1991 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1999 | 2004 |
Fundamental Metrics
Financial Performance| Metric | AUPH | MNKD |
|---|---|---|
| Price | $14.78 | $5.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $17.25 | $10.08 |
| AVG Volume (30 Days) | 939.1K | ★ 3.6M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 0.55 | 0.10 |
| Revenue | $265,808,000.00 | ★ $313,787,000.00 |
| Revenue This Year | $21.76 | $21.40 |
| Revenue Next Year | $16.45 | $25.03 |
| P/E Ratio | ★ $27.01 | $60.37 |
| Revenue Growth | ★ 20.62 | 17.43 |
| 52 Week Low | $6.55 | $3.38 |
| 52 Week High | $16.54 | $6.51 |
Technical Indicators
Market Signals| Indicator | AUPH | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 55.54 |
| Support Level | $14.36 | $5.03 |
| Resistance Level | $15.19 | $6.05 |
| Average True Range (ATR) | 0.49 | 0.26 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 24.06 | 56.42 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.